How do I... facilitate a rapid response to a public health emergency requiring plasma collection with a public–private partnership?

CONVALESCENT plasma; PUBLIC-private sector cooperation; COVID-19 treatment; COVID-19; GENERALIZED estimating equations

In March 2020, there were no treatment options for COVID‐19. Passive immune therapy including anti‐SARS‐CoV‐2 hyperimmune globulin (hIVIG) was a logical candidate for COVID‐19 therapeutic trials, given past success treating emerging pathogens with endogenous neutralizing antibodies. We established a plasma collection protocol for persons recovered from COVID‐19. To speed recruitment in the first U.S. hotspot, Seattle, Washington, federal and state public health agencies collaborated with Bloodworks Northwest to collect convalescent plasma (CP) for manufacturing hIVIG. During March–December 2020, we identified and recruited prospective CP donors via letters to persons recovered from COVID‐19 with laboratory‐confirmed SARS‐CoV‐2 infection. Prospective donors were pre‐screened and administered a medical history survey. Anti‐SARS‐CoV‐2 neutralizing antibody (NAb) titers were classified as qualifying (≥1:80) or non‐qualifying (<1:80) for enrollment based on a live virus neutralization assay. Generalized estimating equations were used to identify characteristics of donors associated with qualifying versus nonqualifying NAb titers. Overall, 21,359 letters resulted in 3207 inquiries, 2159 prescreenings with laboratory‐confirmed SARS‐CoV‐2 infection, and 573 donors (27% of all pre‐screenings with confirmed infection) who provided a screening plasma donation. Of 573 donors screened, 254 (44%) provided plasma with qualifying NAb titers, resulting in 1284 units for hIVIG manufacture. In a multivariable model, after adjusting for other factors, time (60 days) from COVID‐19 symptom onset to screening was associated with lower odds of qualifying NAb (adjusted odds ratio = 0.67, 95% CI: 0.48–0.94). The collaboration facilitated a rapid response to develop and provide hIVIG for clinical trials and CP for transfusion. Only 1 in 12 donor inquiries resulted in a qualifying plasma donation. Challenges included recruitment and the relatively low percentage of persons with high NAb titers and limited screening capacity. This resource‐intensive collaboration may not be scalable but informs preparedness and response strategies for plasma collection in future epidemics. Operational readiness plans with templates for screening, consent, and data collection forms are recommended. [ABSTRACT FROM AUTHOR]

Copyright of Transfusion is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)